An 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the -Blocker Bucindolol in Chronic Heart Failure

Background—Adrenergic activation is an important determinant of outcomes in chronic heart failure. Adrenergic activity is regulated in part by prejunctional 2C-adrenergic receptors (ARs), which exhibit genetic variation in humans. Bucindolol is a novel -AR blocking agent that also lowers systemic norepinephrine and thus is also a sympatholytic agent. This study investigated whether 2C-AR polymorphisms affect sympatholytic effects of bucindolol in patients with heart failure. Methods and Results—In the -Blocker Evaluation of Survival Trial, adrenergic activation was estimated by systemic venous norepinephrine measured at baseline, 3 months, and 12 months posttreatment in patients treated with placebo or bucindolol. In the -Blocker Evaluation of Survival Trial AR polymorphism substudy, DNA was collected from 1040 of the 2708 randomized patients, and 2C-AR gene polymorphisms (2C Del322-325 or the wild-type counterpart) were measured by polymerase chain reaction and gel electrophoresis. Patients who were 2C Del carriers (heterozygotes or homozygotes) exhibited a much greater sympatholytic response to bucindolol (decrease in norepinephrine at 3 months of 15357 pg/mL, P0.012 compared with placebo versus decrease of 5013 pg/mL in 2C wild type, P0.0005 versus placebo; P0.010 by interaction test). 2C Del carriers had no evidence of a favorable survival benefit from bucindolol (mortality compared with placebo hazard ratio, 1.09; 95% CI, 0.57 to 2.08; P0.80), whereas bucindolol-treated subjects who were wild type for the 2C-AR had a 30% reduction in mortality (hazard ratio, 0.70; 95% CI, 0.51 to 0.96; P0.025). Conclusions—In the -Blocker Evaluation of Survival Trial AR polymorphism substudy, the norepinephrine lowering and clinical therapeutic responses to bucindolol were strongly influenced by 2C receptor genotype. (Circ Heart Fail. 2010;3:21-28.)